Athersys

Athersys Accounts Payable

Delisted

The Accounts Payable of Athersys (ATHX) as of Nov 20, 2026 is 37.16 M USD. In the previous year, Accounts Payable was 25.51 M USD — a change of 45.68% (higher).

Accounts Payable

37.16 MUSD

YoY

45.68%

Last updated:

Accounts Payable of Athersys is 2022 37.16 M USD. Accounts Payable of Athersys was 2021 25.51 M USD. It decreases by 45.68% higher compared to the previous year.

The Athersys Accounts Payable history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Accounts Payable
Date
Accounts Payable
Jan 1, 2015
4.32 M USD
Jan 1, 2016
6.88 M USD
Jan 1, 2017
9.31 M USD
Jan 1, 2018
12.80 M USD
Jan 1, 2019
12.99 M USD
Jan 1, 2020
23.09 M USD
Jan 1, 2021
25.51 M USD
Jan 1, 2022
37.16 M USD
The Athersys Accounts Payable history
YEARAccounts PayableYoY
37.16 MUSD+45.68%
25.51 MUSD+10.50%
23.09 MUSD+77.69%
12.99 MUSD+1.49%
12.80 MUSD+37.47%
9.31 MUSD+35.45%
6.88 MUSD+59.11%
4.32 MUSD-6.41%
4.62 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Athersys Stock analysis

What does Athersys do? Athersys Inc. is a biopharmaceutical company based in Cleveland, Ohio. It was founded in 1995 and focuses on the discovery, development, and commercialization of regenerative therapies and cell therapies. The idea for founding Athersys Inc. came from the vision that stem cell therapies could change the way we treat diseases. In the early stages of the company, the team focused on isolating and characterizing human stem cells. Over time, the research evolved and Athersys Inc. shifted its focus to developing drugs that promote tissue and organ regeneration. Athersys Inc.'s business model involves developing stem cell-based medications that are tested in clinical trials. The goal is to combat diseases such as stroke, heart attack, inflammatory diseases, and respiratory syndromes. Athersys Inc. utilizes a proprietary technology platform called MultiStem to isolate, expand, and differentiate stem cells. The company works closely with clinical partners in the pharmaceutical and biotech industry to conduct clinical trials and bring medications to market. Athersys has four divisions: Hematology, Neurology, Pulmonology, and Cardiology. In hematology, Athersys focuses on developing a therapy for cancer treatment. By administering MultiStem, a type of stem cell therapy, they hope to reduce the side effects of chemotherapy and kill cancer cells. In neurology, Athersys focuses on developing medications for the treatment of strokes and neurological disorders. The goal is to trigger regenerative processes in the brain and promote the growth of nerve cells and the regeneration of brain tissue. In pulmonology, Athersys focuses on developing therapies for the treatment of lung diseases such as ARDS and COPD. In cardiology, Athersys aims to improve the healing process after a heart attack by supporting the natural regeneration process of the heart muscle. Athersys' products are still in development and are in various stages of clinical trials. The most well-known product of Athersys is the MultiStem product. The company utilizes its proprietary technology platform to isolate and expand stem cells from human bone marrow and adipose tissue. MultiStem is intended to promote tissue regeneration and reduce inflammation. It has been tested in various preclinical and clinical trials and has shown promising results. Overall, Athersys Inc. is a company that focuses on regenerative therapies and cell therapies. By utilizing its proprietary technology platform MultiStem, Athersys hopes to develop stem cell-based therapies that can contribute to the cure of many different diseases. Although the company is still in the development and study phase, Athersys has already made impressive progress and remains an important player in the biopharmaceutical industry. Athersys is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Athersys stock

Accounts Payable of Athersys is 37.16 M USD in 2022.

Accounts Payable of Athersys changed from 25.51 M USD to 37.16 M USD, representing a 45.68% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Accounts Payable Athersys since 2006 – with annual values, charts, and detailed analysis.

Accounts payable represents money owed to suppliers for goods and services received. It is a key component of working capital management.

Accounts Payable's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Accounts Payable's Athersys historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — Athersys

All Key Metrics — Athersys